找回密碼
 To register

QQ登錄

只需一步,快速開(kāi)始

掃一掃,訪問(wèn)微社區(qū)

123456
返回列表
打印 上一主題 下一主題

Titlebook: Developments in Statistical Evaluation of Clinical Trials; Kees van Montfort,Johan Oud,Wendimagegn Ghidey Book 2014 Springer-Verlag Berlin

[復(fù)制鏈接]
樓主: deferential
51#
發(fā)表于 2025-3-30 10:57:25 | 只看該作者
Mindfulness in Behavioral Healthharmacokinetic exposure-response relationship and (2) dose-response relationship when dose-adjustment depends on potential responses. Dose adjustment often happens in clinical trials either designed for therapeutic dose monitoring, or spontaneously due to, for example, adverse events. It makes causa
52#
發(fā)表于 2025-3-30 14:04:30 | 只看該作者
Realistic Random Direction Mobilityrement. For a continuous outcome variable, a classical GLM for repeated measurements can be used to analyse the difference in development over time between the intervention and control group. However, because GLM for repeated measurements has some major disadvantages (e.g., only suitable for complet
53#
發(fā)表于 2025-3-30 18:28:08 | 只看該作者
54#
發(fā)表于 2025-3-30 22:09:12 | 只看該作者
55#
發(fā)表于 2025-3-31 02:13:43 | 只看該作者
Handbook of Mobile Data Privacycal trials. However, failed past attempts to use surrogate endpoints made it clear that, before deciding on the use of a candidate surrogate endpoint, it is of the utmost importance to investigate its validity. Such validation process has proven challenging for conceptual and practical reasons. In t
56#
發(fā)表于 2025-3-31 08:27:38 | 只看該作者
Handbook of Mobile Data Privacycularly, in oncology. This chapter provides an overview of various biomarker-based designs for phase III randomized clinical trials to evaluate clinical utility of a biomarker or biomarker-based treatment, including biomarker-strategy, enrichment, and randomize-all designs. We also provide a simulat
57#
發(fā)表于 2025-3-31 11:16:09 | 只看該作者
Handbook of Mobile Teaching and Learning such as the continual reassessment method (CRM), have been gradually applied to single-agent trials to determine the maximum tolerated dose (MTD). By contrast, the rule-based approaches have commonly been applied to two-agent combination trials, probably due to the absence of well-understood model-
58#
發(fā)表于 2025-3-31 15:33:15 | 只看該作者
Handbook of Mobile Teaching and Learningally in first or second line of cancer therapies. Basic formulae for the determination of sample sizes based on time to event data can be found in the literature. Assumptions about the distributions of the survival time for OS and PFS, the accrual time and the censoring time are of key importance. M
59#
發(fā)表于 2025-3-31 18:29:15 | 只看該作者
60#
發(fā)表于 2025-4-1 01:44:21 | 只看該作者
Marcello Farina,Riccardo Scattolinid as the dose associated with a certain probability of dose limiting toxicity (DLT) during the first cycle of treatment, although toxicity is repeatedly measured over cycles on an ordinal scale. We present the main dose finding methods developed in the era of cytotoxic agents. We illustrate their pr
123456
返回列表
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務(wù)流程 影響因子官網(wǎng) 吾愛(ài)論文網(wǎng) 大講堂 北京大學(xué) Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點(diǎn)評(píng) 投稿經(jīng)驗(yàn)總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學(xué) Yale Uni. Stanford Uni.
QQ|Archiver|手機(jī)版|小黑屋| 派博傳思國(guó)際 ( 京公網(wǎng)安備110108008328) GMT+8, 2026-1-30 12:29
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復(fù) 返回頂部 返回列表
紫阳县| 大同县| 石棉县| 乡城县| 基隆市| 乌海市| 海晏县| 深水埗区| 观塘区| 中山市| 霍林郭勒市| 含山县| 沁源县| 临朐县| 台山市| 乐至县| 三江| 文成县| 安仁县| 嘉义市| 育儿| 神池县| 黎川县| 南丹县| 赤城县| 吉林省| 长岛县| 汉川市| 贡嘎县| 神池县| 台北县| 石阡县| 宝兴县| 三门县| 白城市| 武山县| 永川市| 全州县| 汉川市| 阜新市| 玉树县|